The expected date of biosimilar entry is based on multiple factors, including:

  • Patent and exclusivity expiry dates.
  • Commercial attractiveness of the target.
  • Biosimilars currently in development.
  • Challenges associated with manufacturing.
  • Japanese price-listing dates.

Table of contents

  • Oncology
    • Market Forecast in the Major Pharmaceutical Markets
      • Terminology of Oncology Monoclonal Antibodies
      • Historical Performance of G-CSFs
      • Terminology of G-CSFs
    • Overarching Forecast Assumptions
      • Overview of Oncology MAb Brands in the Forecast
        • Overview of Approved MAbs in Oncology
      • Overview of Oncology MAb Biosimilars Assumptions
      • Overview of G-CSF Brands in the Forecast
        • Overview of G-CSF Brands
      • Overview of G-CSF Biosimilars Assumptions
        • United States
        • Europe
        • Japan
    • Drug-Specific Forecast Assumptions
      • Avastin
        • Forecast Assumptions
        • Market Forecast: Avastin
      • Cyramza
        • Forecast Assumptions
        • Market Forecast: Cyramza
      • Darzalex
        • Forecast Assumptions
        • Market Forecast: Darzalex
      • Empliciti
        • Forecast Assumptions
        • Market Forecast: Empliciti
      • Erbitux
        • Forecast Assumptions
        • Market Forecast: Erbitux
      • Herceptin
        • Forecast Assumptions
        • Market Forecast: Herceptin
      • Perjeta
        • Forecast Assumptions
        • Market Forecast: Perjeta
      • Rituxan/MabThera
        • Forecast Assumptions
        • Market Forecast: Rituxan/MabThera: Oncology
        • Market Forecast for Rituxan/MabThera: Immunology and Oncology
      • Vectibix
        • Forecast Assumptions
        • Market Forecast: Vectibix
      • Yervoy
        • Forecast Assumptions
        • Market Forecast: Yervoy
      • Neupogen/Gran
        • Forecast Assumptions
        • Market Forecast: Neupogen/Gran
      • Neulasta/G-Lasta
        • Forecast Assumptions
        • Market Forecast: Neulasta/G-Lasta

Author(s): Hamzah Aideed, MSc; Jimmy Jacob; Marta Delgado, PhD

Hamzah Aideed is a Principal Analyst in the biosimilars team at Decision Resources Group. Hamzah’s responsibilities include conducting primary and secondary market research, generating key insights into biosimilars and the biopharmaceutical industry, and providing client support. His work in biosimilars encompasses four key therapy areas – immunology, oncology, endocrinology, and nephrology. Prior to joining DRG, Hamzah was a Senior Research Executive at Consulting at McCann Health, specializing in the design and execution of advanced qualitative and quantitative research methodologies, for bespoke ad-hoc consulting projects. He holds an in Biotechnology & Business Management from the University of Warwick and a in Biological Chemistry from Aston University.  

Jimmy Jacob, is a Business Insights Analyst in the Biosimilars team. Prior to joining DRG, Jimmy worked as a Scientist in Medimmune and Horizon Discovery mostly involving CRIPSR/Cas9 therapeutics. He received his master’s degree in Biotechnology from University of Dundee and his from Imperial College London. His work involved identifying novel molecules that regulated oestrogen receptor-alpha in breast cancer.

Marta Delgado, is a Business Insight Analyst in the Biosimilars Research team, responsible for the analysis of the biosimilars market across four main therapeutic areas – oncology, endocrinology, immunology and nephrology. Marta holds a in Molecular Neuroscience from University College of London (UCL) and a in Biomedicine from University Pompeu Fabra (UPF), Barcelona. Prior to joining the Biosimilars Research team, Marta worked as a Research Analyst at SKIM, specialising in advanced quantitative studies assessing the potential market opportunities to support life sciences companies in their business decision making.


Related Reports

Biomarkers in Oncology | Access & Reimbursement | Detailed, Expanded Analysis: Multi-indication (US)

Biomarker-driven prescribing is paramount in key oncology indications. Biomarkers play an important role and are well-entrenched in indications such as non-small-cell lung cancer and malignant me...

View Details

Biosimilars | Current Treatment | Oncology

In July 2019, Amgen’s Kanjinti (trastuzumab biosimilar) and Mvasi (bevacizumab biosimilar) were the first monoclonal antibody (MAb

View Details

Biosimilars | Access & Reimbursement | Oncology

This report is available to find out more click the link and fill out the form to get more details.

View Details

Biosimilars | Emerging Biosimilars | Oncology: Trastuzumab Biosimilars Launch Tracking (Germany) Wave 3

Celltrion’s Herzuma was the first biosimilar of Roche’s Herceptin, a blockbuster HER2-targeted therapy, to launch in Europe. A few months later, three additional trastuzumab biosimila...

View Details